China Pharma Holdings (CPHI) Price to Earnings (2010 - 2026)

China Pharma Holdings (CPHI) has reported Price to Earnings for 17 consecutive years, with 18.34 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 65.97% year-over-year to 18.34; the trailing twelve-month figure through Jun 2026 stood at 5.98 (down 274.24% YoY), and the FY2025 full-year result was 2.17, down 90.03% from the prior year.
• Price to Earnings eased to 18.34 in Q2 2026 per CPHI's latest filing, from 13.66 in the prior quarter.
• Across five years, Price to Earnings topped out at 1.66 in Q4 2023 and bottomed at 18.34 in Q2 2026.
• Historically, Price to Earnings has averaged 8.0 across 5 years, with a median of 6.34 in 2023.
• The sharpest annual moves came in 2022 and 2025: Price to Earnings soared 82.88% in 2022, then tumbled 272.64% in 2025.
• Over 5 years, Price to Earnings stood at 3.99 in 2022, then jumped by 58.34% to 1.66 in 2023, then sank by 99.61% to 3.32 in 2024, then declined by 28.13% to 4.25 in 2025, then tumbled by 331.69% to 18.34 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 18.34, 13.66, and 4.25 for Q2 2026, Q1 2026, and Q4 2025 respectively.